Glint Pharmaceuticals to Begin Clinical Testing on Contact Lens to Prevent COVID-19 Virus Infection

UF startup Glint Pharmaceuticals, an ophthalmic pharmaceutical company that delivers medicated contact lenses to treat eye diseases, has developed a patented technology for delivery of an anti-COVID-19 formulation to the ocular surface to prevent and treat infections.

The proprietary formulation combines a well-tolerated ocular chemistry with the Glint drug delivery contact lens to kill a broad range of bacteria and viruses including COVID-19. The formulation has been demonstrated to effectively reduce virus infection in scientific and medical publications and has been reviewed for effectiveness by the FDA.

Learn more about Glint Pharmaceuticals to Begin Clinical Testing on Contact Lens to Prevent COVID-19 Virus Infection.